Ra Pharmaceuticals Inc  

(Public, NASDAQ:RARX)   Watch this stock  
Find more results for RARX
13.94
-0.33 (-2.28%)
Real-time:   12:34PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.85 - 14.33
52 week 11.20 - 27.84
Open 14.33
Vol / Avg. 25,521.00/134,814.00
Mkt cap 315.53M
P/E     -
Div/yield     -
EPS -2.47
Shares 22.63M
Beta     -
Inst. own 83%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -585.71%
Operating margin - -568.67%
EBITD margin - -542.29%
Return on average assets -61.66% -38.19%
Return on average equity -68.55% -72.14%
Employees 46 -
CDP Score - -

Address

87 Cambridgepark Dr
CAMBRIDGE, MA 02140-2311
United States - Map
+1-617-4014060 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.

Officers and directors

Douglas A. Treco Ph.D. President, Chief Executive Officer, Co-Founder, Director
Bio & Compensation  - Reuters
Jeffrey Johnston M.D. Senior Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Alonso Ricardo Ph.D. Senior Vice President of Research & Development
Bio & Compensation  - Reuters
Kerry Black Executive Director, Operations
Bio & Compensation  - Reuters
Edward T. Mathers Board Member
Age: 57
Bio & Compensation  - Reuters